TMS Clinical Study Results
Proven Efficacy Across 30+ Randomized Controlled Trials & 40+ Clinical Sites
FDA-cleared since 2008, Transcranial Magnetic Stimulation is backed by robust data demonstrating remarkable response and remission rates for patients with treatment-resistant depression.
Extensive Scientific Evidence for Prefrontal Stimulation
TMS Therapy was cleared by the FDA in 2008 following a decade of clinical trials. The administration of TMS is highly standardized, precise, and well-regulated.
The evidence supporting prefrontal cortical stimulation spans over 30 randomized, controlled trials involving thousands of patients worldwide. Below are three representative clinical studies totaling 462 patients treated across 40+ clinical centers nationwide.
Average Clinical Response Rate
Full Remission Rate
Patients in Featured Studies
3 Key Clinical Studies
Real-world clinical data from academic medical centers and private psychiatric practices.
Study 1: Dunner et al. (2014)
Multisite Observational Study Across 42 Private & Academic Clinics (n = 257)
In a naturalistic clinical trial of 257 patients who had failed prior antidepressant medications, TMS Therapy delivered durable effectiveness over 1 year following acute treatment. At 12 months post-acute care, response rates reached 67.7% and remission reached 45.1% with occasional reintroduction treatments.
Study 2: Vaché et al. (2013)
Austin TMS Clinic Retrospective Evaluation (n = 82)
In this study, 82 patients with severe treatment-resistant depression (50% with prior psychiatric hospitalizations) were evaluated using the IDS-SR30 scale. Average symptom scores dropped from 42.8 down to 20.1, with 67.1% responding and 46.3% entering full clinical remission.
Study 3: Cress et al. (2015)
TMS Serenity Center Clinical Trial (n = 123)
In 123 patients with unipolar major depressive disorder, baseline Beck Depression Inventory (BDI-II) scores dropped from 25.6 (moderate depression) down to 10.2 (remission). Over 72.4% reached full remission, with 80%+ of evaluated patients maintaining remission over 4 years.
Ongoing Research & Additional Indications
TMS Therapy has undergone, or is currently undergoing, hundreds of additional clinical trials for psychiatric and neurological conditions including: PTSD, OCD, Anxiety, Bipolar Disorder, Autism Spectrum Disorder, Chronic Pain, Fibromyalgia, Smoking Cessation, and Mild Cognitive Impairment.
Leading medical research institutions—including Columbia, Duke, Harvard, Johns Hopkins, Mayo Clinic, Stanford, UCLA, University of Pennsylvania, and Walter Reed National Military Medical Center—continue to expand clinical protocols for targeted neuromodulation.
Explore Related TMS Resources
What is TMS Therapy?
Understand how TMS works
Is TMS Right for Me?
Candidacy and screening
Typical TMS Treatment
What a course looks like
TMS Clinical Study Results
Research findings
About Depression
Understanding the condition
Depression Symptoms
Recognizing the signs
Treating Depression
Treatment approaches
Videos & Media
Watch patient stories
Financing Options
Payment and financing
Supplemental Research
Additional studies and data
Virtual Education
Online learning resources
SAINT® Accelerated TMS
FDA-cleared, 5-day accelerated TMS protocol
Standard TMS Therapy
Non-invasive magnetic stimulation for depression
SPRAVATO® (Esketamine)
FDA-approved nasal spray for TRD
Prism for PTSD
EEG neurofeedback for PTSD symptoms
Proliv®Rx At-Home TMS
At-home neuromodulation device
Ampa One System
Single-day accelerated TMS protocol
IV Ketamine Infusions
Rapid-acting IV ketamine therapy
Ketamine-Assisted Psychotherapy
KAP combines ketamine with therapy
PrTMS Therapy
Personalized repetitive TMS
Psychotherapy & Counseling
CBT, DBT, EMDR, and more
Medication Management
Psychiatric medication oversight
Ampa One Day Accelerated Protocol
Single-day accelerated protocol
TMS for Depression
FDA-cleared TMS for treatment-resistant depression
TMS for Anxiety
Non-drug neuromodulation for anxiety
TMS for PTSD
Targeted stimulation for trauma circuits
TMS for OCD
SmartFocus® 3D targeting for OCD
Let's find your path forward — together
Reaching out is the hardest part, and you've already started. Tell us a little about yourself and our compassionate care team will reach out within one business day to answer your questions, verify your insurance, and help you take the next step — at no cost and no obligation.
Two pathways to care: self-pay offers the fastest access (most patients start within days, with appointments available seven days a week), or we accept Blue Cross Blue Shield in select states and the BCBS Federal Employee Program in select states. We'll help you find the right path for your situation.
- Warm, judgment-free consultation — no pressure, just answers
- Flexible scheduling: Zoom or in-person, including weekends
- Same-day or next-day appointments often available